Evidence map›Paper›PMID 31588509›Full record

ArticleBriefings in bioinformatics2020

MutEx: a multifaceted gateway for exploring integrative pan-cancer genomic data.

Jie Ping, Olufunmilola Oyebamiji, Hui Yu, Scott Ness, Jeremy Chien, Fei Ye, Huining Kang, David Samuels, Sergey Ivanov, Danqian Chen and 2 more

Abstract read
In one paragraph

Article in Briefings in bioinformatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Comprehensive Pan-Cancer Mutation Density Patterns in Enhancer RNA.International journal of molecular sciences · 2023
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jie PingDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, USA, 37232.
Olufunmilola OyebamijiComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA, 87109.
Hui YuComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA, 87109.
Scott NessComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA, 87109.
Jeremy ChienComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA, 87109.
Fei YeDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, USA, 37232.
Huining KangComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA, 87109.
David SamuelsDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, USA, 37232.
Sergey IvanovDepartment of Internal Medicine, Vanderbilt University, Nashville, USA, 37232.
Danqian ChenKey Laboratory of Resource Biology and Biotechnology in Western China, School of Life Sciences, Northwest University, Xi'an, Shaanxi 710069, China.
Ying-Yong ZhaoKey Laboratory of Resource Biology and Biotechnology in Western China, School of Life Sciences, Northwest University, Xi'an, Shaanxi 710069, China.
Yan GuoComprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA, 87109.

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Mutations and Target Genes in Adenoid Cystic CarcinomaR01DE023222 · NIDCR · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Viswanathan Palanisamy · 2012 to 2026
$5.6M
NCI NIH HHS P30 CA118100NIDCR NIH HHS R01 DE023222
6 · The paper itself

Abstract

Somatic mutation and gene expression dysregulation are considered two major tumorigenesis factors. While independent investigations of either factor pervade, studies of associations between somatic mutations and gene expression changes have been sporadic and nonsystematic. Utilizing genomic data collected from 11 315 subjects of 33 distinct cancer types, we constructed MutEx, a pan-cancer integrative genomic database. This database records the relationships among gene expression, somatic mutation and survival data for cancer patients. MutEx can be used to swiftly explore the relationship between these genomic/clinic features within and across cancer types and, more importantly, search for corroborating evidence for hypothesis inception. Our database also incorporated Gene Ontology and several pathway databases to enhance functional annotation, and elastic net and a gene expression composite score to aid in survival analysis. To demonstrate the usability of MutEx, we provide several application examples, including top somatic mutations associated with the most extensive expression dysregulation in breast cancer, differential mutational burden downstream of DNA mismatch repair gene mutations and composite gene expression score-based survival difference in breast cancer. MutEx can be accessed at http://www.innovebioinfo.com/Databases/Mutationdb_About.php.

Indexed as

GenomicsComputational BiologyDatabases, GeneticHigh-Throughput Nucleotide SequencingHumansMutationNeoplasmsProgramming LanguagesSurvival Analysisgene expressionsomatic mutationsurvival

Identifiers

PMID31588509
PMCPMC7373173

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.